Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Menstrual blood multiomics analysis to better diagnose, understand and treat endometriosis

Project description

Diagnosis of endometriosis through the menstrual fluid

Endometriosis is a condition where endometrial cells grow in other places within the abdomen and pelvic area. This causes significant pain and is associated with infertility, affecting up to 10% of women. Funded by the European Research Council, the MultiMENDO project aims to shed light on the pathogenesis of endometriosis and improve diagnosis. Researchers propose to use menstrual fluid for the diagnosis of endometriosis. Through a transcriptomics analysis, they will identify candidate diagnostic biomarkers associated with endometriosis as well as prognostic biomarkers for response to treatment. The work will advance current knowledge on the pathophysiology of endometriosis and open the way for new treatments.

Objective

The MensEndoDiag project aims at finding diagnostic biomarkers and prognostic biomarker candidates, as well as investigating new therapeutic approaches for endometriosis using menstrual fluid, an easily accessible yet overlooked biological fluid.
Endometriosis is a common gynecological disorder affecting 6-10% of women of childbearing age. It is associated with pelvic pain and infertility. It leads to a reduced quality of life and is an economic burden. It is defined by the presence of endometrial tissue outside the uterus. Endometriotic lesion form from retrograde menstruation (menstrual fluid reflux through the fallopian tubes) but the precise pathogenesis remains unclear. There are no noninvasive biomarkers currently used in clinical care but they are essential to improve the diagnosis delay, currently estimated at 8 years. There is no specific treatment and pharmacological options are contraceptive. Here, I propose to use menstrual fluid as a relevant biological fluid for endometriosis.
In Aim 1, single-cell transcriptomics and soluble protein multiplex assays on 64 menstrual fluid samples will be used to identify candidate diagnostic biomarkers that differentiate endometriosis affected women from healthy controls. Validation of these biomarkers will be carried out in menstrual fluid samples from 250 women. In Aim 2, menstrual fluid derived organoids cultured with or without immune cells will be used to assess endometriosis associated functional changes and to test new immunomodulatory treatments. In Aim 3, longitudinal cohorts will be established to identify prognostic candidate biomarkers for response to surgery and in vitro fertilization.
Diagnostic and prognostic biomarkers are essential to assess disease establishment, evolution and to choose the most appropriate treatment. This project will enhance our understanding of endometriosis pathophysiology as well as allow the study of a new biological fluid, relevant to gynecologic and reproductive disorders.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

UNIVERSITE PARIS CITE
Net EU contribution
€ 1 058 130,50
Address
85 BD SAINT GERMAIN
75006 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 058 130,50

Beneficiaries (2)